Evidence OSMedical evidence & research
中文Custom request
Evidence OSUse cases & deliverables
Back to customer servicesPatients and families facing a major decision

Overseas care may cost a great deal. What could it add to the current proposal?

You have a local diagnosis or plan and want to compare medical additions, timing and record requirements before paying for outside consultation, travelling or changing treatment.

How does this scope address your concerns?

Travelling abroad is not automatically better. I want to know whether the added expense may buy a new route, trial access, diagnostic review or the same treatment in another location.

When this scope fits
  • A local treating team and diagnostic records, with cross-country options to compare
  • Willingness to confirm institutional eligibility and fees directly, without treating a candidate list as a guaranteed appointment or trial place
When the scope needs adjusting
  • Immediate danger, acute deterioration or care that cannot wait: emergency and treating teams must act first; evidence work must not delay care
  • Expecting the platform to replace pathological diagnosis or prescribing, or guarantee treatment success
  • Expecting a guaranteed specialist appointment, visa, trial place or critical-care transport
REAL SOURCES · ILLUSTRATIVE REQUEST · DOWNLOADABLE SAMPLE

Overseas cell therapy: establish the treatment difference before cost

Download sample packZIP

From regulatory evidence to access feasibility

01Disease and previous therapy

FDA announcement specifies melanoma and prior-treatment criteria

02Treatment difference

Compare actual mechanisms and available routes rather than countries

03Individual eligibility and acceptance

Organ status, center evaluation and acceptance: awaiting center reply

04Total cost and follow-up

Treatment, travel, caregiver, complications and local follow-up: direct quotes needed

A worked verification example using the 2024 FDA Amtagvi announcement. No hospital quote, appointment or individual acceptance is confirmed.

CheckFinding / sample contentUse
What evidence answersThe announcement reports objective response and response durationIt is not a direct comparison with local options
What remains unansweredIndividual benefit and eligibility to travel are not establishedPut unknowns into bilingual center questions
Budget handlingHospital, translation, travel and follow-up require separate quotesDo not present guessed prices as actual costs
SOURCES USED IN THIS EXAMPLE
  1. FDA: Amtagvi approval evidence (16 Feb 2024)
Prepared 5 Oct 2026 · Selected references, not an exhaustive systematic search

Major decisions: the work and payment flow

One decision stage is one work package. Begin with appraisal, then decide whether to continue. The contract defines each deliverable, payment and review responsibility.

  1. 01

    Free scope discussion

    Confirm the decision, deadline and service fit.

    Payment timingFree; overview only
  2. 02

    Records & question appraisal

    Receive facts, gaps, key questions and a scope proposal. You may stop here.

    Payment timingPay before appraisal; credit toward the same scope
  3. 03

    Evidence & option comparison

    Receive benefits, risks, patient fit and a source matrix.

    Payment timingStart payment after agreeing scope, reviewers and timing; progress payment at the draft milestone
  4. 04

    Relevant specialty review

    Receive review findings, corrections and unresolved questions.

    Payment timingIncluded review is not charged again
  5. 05

    Two reports & discussion

    Clinician and family reports, one discussion and agreed clarification.

    Payment timingFinal payment at the agreed delivery milestone

Payment example for one packageCNY 48,000

Illustrative budget including appraisal; shows instalments, not a completed engagement or a standard price.

Scope assessmentCNY 3,000
Start after scope and reviewers are confirmedCNY 15,000
Evidence draftCNY 18,000
Delivery and in-scope clarificationCNY 12,000

CNY 29,800–98,000 is the proposed reference range for one defined decision-stage package, rather than a fee for each step. The CNY 48,000 example includes CNY 3,000 appraisal plus CNY 45,000 subsequent work, with the agreed specialty review included.

Scope & acceptance

Work covered by the quote

  • Pilot policy: CNY 3,000 assessment, credited against a same-scope commission; stage CNY 50,000–150,000
  • Baseline: 1 person, 1 stage, 3 local/overseas routes, 5 questions, 100 record pages and 40 priority sources
  • One Chinese decision brief, one English clinical summary, 2 discussions and one clarification round
  • Consultation, treatment, professional translation, travel, visa and transport charges are itemized separately
  • Public pages support candidate verification only; institutions confirm acceptance, appointments, trial eligibility and formal fees
  • No partnership, clinician availability or privileged access to listed overseas institutions is claimed

Acceptance criteria

  • Each comparison row maps to a patient record or reference, with search cutoff, population fit and remaining gaps. Drafts do not make decisions reserved for clinicians and patients.

Checking the evidence

  • Retain identifiable original sources, authorised inputs and missing information.
Workflow and inputs

From inputs to delivery

Explore the workflow and deliverable structure. This preview does not run searches, read real records or produce medical findings.

01 / WORKFLOW PREVIEW

Define the question and available time

Confirm authorization, the waiting window allowed by the treating team, records, candidate routes, up to five questions and specialist review responsibilities. Do not accept this stage if delivery cannot fit the clinical deadline.

Agree scope before commissioning
Methods, sources and professional responsibilities
THE BASIS FOR THIS SCOPE

Why this approach? Inspect the basis.

Consequential treatment decisions need both research evidence and a review of whether it applies to you.

OFFICIAL GUIDANCE

NCI · Cancer Treatment

National Cancer Institute / NIH

Cancer treatment options and clinical trials

Explore treatment types, treatment questions and clinical trials, then identify choices to discuss with the treating team.

Scope & access conditions

Public patient information cannot determine your best treatment. Pathology, stage, prior treatment and professional assessment remain necessary.

Open official source
OFFICIAL GUIDANCE

NICE · NG56

NICE · United Kingdom

Recheck applicability when conditions coexist

Single-condition evidence may come from populations with fewer coexisting conditions. Consider treatment burden, goals, benefits and harms.

Scope & access conditions

This supports the need to review applicability; it does not establish the effectiveness of a new treatment strategy.

Open official source
OFFICIAL GUIDANCE

NICE · NG197

NICE · United Kingdom

Discuss options, benefits and risks

Shared-decision guidance addresses benefits, risks, consequences, uncertainty and personal preferences.

Scope & access conditions

This is UK decision-support guidance, not a treatment conclusion for an individual or validation of EOS service outcomes.

Open official source
PUBLIC DATABASE

ClinicalTrials.gov

NLM / NIH

Check studies and reported results

Review study objectives, eligibility, locations, status and reported results, then identify questions for the clinical team.

Scope & access conditions

Sponsors or investigators submit the records. A listing is not government approval of safety or effectiveness, or a determination that you should participate.

Read the official description
Open official source

These references support problem definition and evidence appraisal. Your conclusions still require project-specific sources and professional review.

The value of this commissionBefore payment or travel, check the medical addition over local routes, compare evidence and unconfirmed conditions, and prepare bilingual records for reuse across institutions.

Evidence consulting for overseas care choicesCompare alternatives and value

You can commit a substantial treatment budget, but first want to know what overseas care may add medically.

What to assessMSK International Patient ServicesEvidence OS · Commissioned scope
Service focusMSK’s current page presents in-person international care and coordination. No uniform fee or current international remote opinion was displayed on the reviewed page.Before payment or travel, check the medical addition over local routes, compare evidence and unconfirmed conditions, and prepare bilingual records for reuse across institutions.
When to chooseActual institutional intake, care planning, financial explanation, language support and travel coordination.Pilot baseline: one person, one defined decision stage, up to 3 local/overseas routes or institution proposals, 5 questions, 100 usable record pages and 40 priority sources; one Chinese decision brief and one English clinical summary, 2 agreed discussions and one clarification round. Institutions confirm current eligibility, formal clinical opinions and their own quotes.
What the fee pays for
Assessment CNY 3,000; stage CNY 50,000–150,000. Agree new institutions, proposals, opinion reviews or record changes before work. Identify and credit reusable work first. Travel and hospital admission are not required next purchases.
Value beyond this task
Evidence differences after outside opinions and questions about continuity with local care. Illustrative service total CNY 88,000 includes CNY 3,000 assessment; external consultation, treatment, professional translation, travel and transport are excluded. Confirm hospital eligibility and prices directly; no partnership or appointment access is claimed.
How to assess value
Check responses to the agreed questions, traceable sources, record gaps and differing opinions. For overseas routes, also check incremental services and third-party fees. Clinical outcomes are not consulting acceptance criteria.

No guaranteed appointment, visa, trial enrolment, medicine access, transport or outcome. Hospital, clinician, professional translation and travel charges are separate. Institutions verify referral and practice requirements. Treating and transport clinicians determine fitness for critical-care transfer.

CHECK THE OFFICIAL SERVICE SCOPEMemorial Sloan Kettering Cancer Center · Services for International PatientsMemorial Sloan Kettering Cancer Center · Frequently Asked Questions – International Patients
Reuse and updates after delivery
  • If the patient stays with local care, the evidence dossier and bilingual summary can still support local consultations. Agree actual reuse rights and additional work in the contract.

Agree reuse rights, retention and export periods, and future update fees when scoping.

Questions before commissioning

Will you arrange an overseas hospital?

The current service preview covers evidence consulting and preparation. Any appointment, formal clinical opinion, treatment, visa or transport coordination requires separate confirmation of provider, authorization, availability and fees. Listing an institution does not imply a partnership.

Why not compare hospital rankings alone?

A ranking cannot establish suitability of a treatment for this patient. We compare proposals, patient fit, eligibility and checkable conditions in one table.

How do your fees relate to hospital fees?

EOS fees are defined by evidence work; third-party charges are separate. Disclose any referral interests or commissioning relationships before contracting. Choosing overseas care is not our completion criterion.

Define the delivery for your actual question.

Add your goal, available inputs and timing. Agree scope, review responsibilities and a quote before commissioning.

Request scope & quote
Explore other situations
Patients and families facing a major decision

After a cancer diagnosis, several treatment routes sound reasonable. How should we compare them?

Proposed delivery: patient-specific evidence comparison for this choice, clinician and family materials, and consultation questions.

Assessment CNY 3,000; stage CNY 29,800–98,000See the deliverable
Patients and families facing a major decision

Serious illness, major surgery and several conditions overlap. Does the standard route fit this patient?

Proposed delivery: conflicting goals, risks and evidence applicability compared, with questions for the multidisciplinary team.

Assessment CNY 3,000; stage CNY 29,800–98,000See the deliverable
Patients and families facing a major decision

Evidence for a rare condition is scarce. Which “new treatments” are worth asking our clinician about?

Proposed delivery: diagnostic and treatment questions, evidence-level comparisons and checkable specialist/trial candidates with eligibility questions.

Assessment CNY 3,000; stage CNY 29,800–98,000See the deliverable
Patients and families facing a major decision

Two specialists proposed different routes. Clarify the disagreement before deciding.

Proposed delivery: opinion–evidence–patient-fit matrix, key unknowns and targeted questions for the treating team.

Assessment CNY 3,000; stage CNY 29,800–98,000See the deliverable
Patients and families facing a major decision

Understand one report and prepare clear appointment questions.

Proposed basic support: a sourced record-explanation draft, missing information and appointment questions.

CNY 99 per requestSee the deliverable
Patients and families facing a major decision

Follow-up records keep arriving. Keep each change organized.

Proposed basic support: a personal record timeline, automated version-change summary and follow-up questions.

CNY 199 setup + CNY 69 per monthSee the deliverable